PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the first paragraph were incorrect. The corrected release follows: BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on January 23, 2026, the compensation committee of BridgeBio’s board of directors approved e ...

Core Viewpoint - Rakovina Therapeutics Inc. is undergoing significant corporate updates, including leadership changes, debt restructuring, and financing initiatives to strengthen governance and enhance capital markets execution [1]. Debt Restructuring - The maturity date of the 12.0% convertible debentures, totaling $1,454,000, has been extended from January 28, 2026, to March 11, 2026, with consent from holders representing at least 66 2/3% of the outstanding principal [2][3]. - The company plans to restructure the outstanding 2023 Debentures, offering holders the option to convert their debentures into new Replacement Debentures or settle through a shares-for-debt conversion at $0.12 per share [4][5]. - An agreement in principle has been reached with an existing investor for an additional $1.0 million investment through a private placement of unsecured convertible debentures [7]. Financing Initiatives - The company proposes a concurrent private placement of up to 5,000,000 common shares at $0.12 per share, aiming for additional gross proceeds of up to $500,000 [9]. - The proceeds from the private placements will be used for near-term working capital to support ongoing corporate activities and strategic initiatives [10]. Leadership Changes - Kim Oishi has been appointed as the new Chief Executive Officer and will also join the Board of Directors, bringing extensive experience in public company leadership and capital markets strategy [11][12]. - Frank Holler has been appointed as an independent director, contributing significant expertise in life sciences and governance [16][18][21]. - Jeffrey Bacha will continue as the non-executive Chair of the Board, ensuring continuity and strategic oversight [13][15]. Board Composition - Dr. Dennis Brown has stepped down from the Board but will continue as Chair of the Scientific Advisory Committee, while Al DeLucrezia has also stepped down but will remain as an advisor [23][24]. - The Board's recent changes are aimed at enhancing governance and supporting the company's strategic initiatives in oncology [25][26]. Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments that target the DNA damage response, utilizing advanced computational chemistry and AI-enabled drug discovery platforms [27].

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the second quarter of 2026. Payment will be made on April 7, 2026, to shareholders of record at the close of business on March 16, 2026. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-e ...

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. (“Quantum” or the “Company”) (NASDAQ: QNTM).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether ...

Key Takeaways KROS is advancing KER-065 for DMD, with FDA orphan drug status and a phase II trial planned for early 2026.DYN reported positive data for z-rostudirsen, showing dystrophin gains and functional improvements in DMD.DYN held $791.9M in cash as of Sept. 2025, funding operations into Q3 2027, alongside multiple programs.Keros Therapeutics (KROS) is a clinical-stage biopharmaceutical company developing innovative therapies for patients with disorders caused by abnormal signaling within the transform ...

Summary of Cardiff Oncology Update Call Company Overview - **Company**: Cardiff Oncology (NasdaqCM:CRDF) - **Focus**: Development of onvansertib, a highly specific oral PLK1 inhibitor, primarily for RAS-mutated metastatic colorectal cancer (mCRC) patients Key Points Management Transition - Cardiff Oncology announced a management transition to better position the company for late-stage development of onvansertib [5][6] - Mani Mohindru appointed as Interim CEO, emphasizing the need for leadership aligned with the company's evolving operational and financial needs [4][5] Clinical Trial Updates - Promising phase 2 data from the CRDF-004 trial for onvansertib in first-line RAS-mutated mCRC patients was discussed [5][7] - The trial evaluated onvansertib in combination with standard care regimens (FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab) [8] - Dose-dependent benefits observed, particularly with the 30 mg dose of onvansertib combined with FOLFIRI plus bevacizumab, showing an overall objective response rate of 72.2% compared to 43.2% with FOLFOX and 42.1% with FOLFIRI alone [10][11] Efficacy and Safety Data - Median progression-free survival (PFS) has not yet been reached in the onvansertib arms, indicating extended benefit compared to a median PFS of about 11 months for standard care [10] - The PFS hazard ratio was reported at 0.37 for the 30 mg onvansertib plus FOLFIRI bev arm, indicating a significant reduction in disease progression risk [11] - Safety profile remains favorable, with no unexpected toxicities reported; grade 3 or higher adverse events were infrequent [12] Future Plans - Cardiff plans to initiate a registrational study later in 2026, comparing onvansertib plus FOLFIRI to standard care regimens [12][14] - The study protocol will likely include both FOLFIRI and FOLFOX in the control arm to provide comprehensive data for regulatory review [13] - Anticipation of more mature clinical data from the CRDF-004 study by mid-2026 [14] Strategic Considerations - Discussions regarding potential partnerships to support the phase 3 trial and broaden development beyond initial indications are ongoing [33] - The company is focused on building a leadership team with experience in late-stage development and commercialization [76] Additional Insights - The transition in leadership is not due to issues with onvansertib but rather a strategic move to capitalize on promising data [6] - The focus on durability of response is emphasized, with stable disease being a significant factor in treatment efficacy [24][25] - The company is committed to maintaining operational continuity during the management transition [7] Conclusion Cardiff Oncology is positioned for significant growth with onvansertib, supported by promising clinical data and a strategic management transition aimed at enhancing its late-stage development efforts. The upcoming registrational study and potential partnerships are critical steps in advancing the drug's market potential.

Core Insights - INmune Bio, Inc. has made significant progress in 2025, focusing on developing therapies for neuroinflammatory and immunologic diseases, particularly through its programs XPro™ for Alzheimer's disease and CORDStrom™ for Recessive Dystrophic Epidermolysis Bullosa (RDEB) [1][10] CORDStrom™ Program - CORDStrom™, an allogeneic umbilical cord-derived mesenchymal stromal cell therapy for RDEB, achieved substantial progress in 2025, including successful completion of three commercial pilot-scale runs in preparation for regulatory filings [2] - The company plans to submit a Marketing Authorization Application (MAA) to the UK's Medicines and Healthcare products Regulatory Agency (MHRA) by mid-summer 2026, followed by a Biologics License Application (BLA) to the U.S. FDA towards the end of 2026 [2][3] XPro™ Program - XPro™ demonstrated potential as a differentiated therapy for Alzheimer's disease, with a Phase 2 study (MINDFuL) revealing meaningful signals in a predefined subpopulation of amyloid-positive early AD patients [4][6] - In this subpopulation, XPro™ showed an effect size of 0.27 on the EMACC cognitive scale after 6 months, which compares favorably to the effect sizes of approved anti-amyloid therapies [6][7] - The results support XPro's proposed mechanism of action, which involves selectively inhibiting soluble TNF to reduce neuroinflammation while preserving beneficial TNF signaling [8] Financial Position - As of September 30, 2025, INmune Bio had approximately $27.7 million in cash and cash equivalents, positioning the company well for continued execution and enabling it to achieve key milestones through year-end 2026 [9]

Core Insights - Propanc Biopharma, Inc. has filed its fourth new provisional patent application in two months, focusing on innovative formulations of pancreatic proenzymes, which are critical for addressing challenges in stability and transport for biomedical applications [1][2] - The company aims to double its intellectual property portfolio from approximately 90 to over 200 patents, covering various aspects of its proenzyme technology, which targets and prevents metastasis from solid tumors [2][3] - Propanc's lead asset, PRP, is designed to selectively attack cancer stem cells and circulating tumor cells while sparing healthy tissue, offering a potential long-term therapy with reduced toxicity compared to conventional treatments [3][4] Company Developments - The recent patent applications are part of a strategy to secure leadership in a field with significant unmet medical needs, particularly for aggressive cancers with limited treatment options [2][3] - Preparations for a Phase 1b First-In-Human study of PRP in advanced cancer patients are advancing rapidly, with expectations for further updates on the clinical pathway and broader pipeline soon [3] Industry Context - Propanc is developing a novel approach to cancer treatment by targeting cancer stem cells through proenzyme activation, which addresses the underlying drivers of cancer proliferation and spread [4]

MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress to be held January 28 through February 1, 2026, in Dublin, Ireland. The presentations highlight clinical data in pulmonary arterial hypertension (PAH) and pulmonary hypertension as ...

Arcutis Biotherapeutics (ARQT) announced that on January 23, 2026, the Company and Kowa Pharmaceuticals America mutually agreed to terminate their promotion agreement. The agreement covered sales and promotion of ZORYVE by Kowa to primary care physicians and pediatricians in the United States. Following the termination, Arcutis plans to assume responsibility for sales and promotion of ZORYVE in the pediatric and primary care settings. The Company is finalizing its plans for promotion to these clinicians an ...